These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 29767487)

  • 1. Melanoma in female patients: general features and focus on the impact of estro-progestinic pills in prognostic factors.
    Paolino G; Moliterni E; Didona D; Corsetti P; Lopez T; Abbenante D; Calvieri S; Bottoni U
    G Ital Dermatol Venereol; 2018 Aug; 153(4):582-585. PubMed ID: 29767487
    [No Abstract]   [Full Text] [Related]  

  • 2. [Hormonal contraceptives].
    Carlotti N
    Rev Prat; 2008 Jan; 58(1):21-8. PubMed ID: 18326358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re: Breast cancer risk in relation to the interval between menopause and starting hormone therapy.
    Grant EC
    J Natl Cancer Inst; 2011 Jul; 103(13):1069; reply 1069-70. PubMed ID: 21700925
    [No Abstract]   [Full Text] [Related]  

  • 4. Population Reports. Lower-dose pills.
    Popul Rep A; 1988 Nov; (7):1-31. PubMed ID: 3076873
    [No Abstract]   [Full Text] [Related]  

  • 5. The sexuological impact of hormonal contraceptives based on their route of administration.
    Guida M; Di Carlo C; Troisi J; Gallo A; Cibarelli F; Martini E; Tiranini L; Nappi RE
    Gynecol Endocrinol; 2017 Mar; 33(3):218-222. PubMed ID: 27908210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weighing the Risks and Benefits of Hormonal Contraception.
    Peachman RR
    JAMA; 2018 Mar; 319(11):1083-1084. PubMed ID: 29490363
    [No Abstract]   [Full Text] [Related]  

  • 7. [New results in the field of hormonal contraceptives].
    Lauritzen C
    Med Welt; 1975 Mar; 26(11):486-93. PubMed ID: 1121248
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacodynamics of combined estrogen-progestin oral contraceptives: 1. Effects on metabolism.
    Bastianelli C; Farris M; Rosato E; Brosens I; Benagiano G
    Expert Rev Clin Pharmacol; 2017 Mar; 10(3):315-326. PubMed ID: 27977304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Follicular ovarian cysts appearing during progestin or estroprogestin oral contraception at low doses].
    Netter A; Gabriel R
    Bull Acad Natl Med; 1988 May; 172(5):711-5. PubMed ID: 3056584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics of combined estrogen-progestin oral contraceptives: 2. effects on hemostasis.
    Farris M; Bastianelli C; Rosato E; Brosens I; Benagiano G
    Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1129-1144. PubMed ID: 28712325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral contraceptives and coronary heart disease: modulation of glucose tolerance and plasma lipid risk factors by progestins.
    Crook D; Godsland IF; Wynn V
    Am J Obstet Gynecol; 1988 Jun; 158(6 Pt 2):1612-20. PubMed ID: 3287933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of ethinylestradiol dose and progestagen in combined oral contraceptives on plasma sex hormone-binding globulin levels in premenopausal women.
    Stegeman BH; Raps M; Helmerhorst FM; Vos HL; van Vliet HA; Rosendaal FR; van Hylckama Vlieg A
    J Thromb Haemost; 2013 Jan; 11(1):203-5. PubMed ID: 23122048
    [No Abstract]   [Full Text] [Related]  

  • 13. Does use of estrogens decrease the Breslow thickness of melanoma of the skin? Oral contraceptives and hormonal replacement therapy.
    Koomen ER; Joosse A; Herings RM; Casparie MK; Guchelaar HJ; Nijsten T
    Melanoma Res; 2009 Oct; 19(5):327-32. PubMed ID: 19593232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormonal contraception: the current situation.
    Elstein M
    Practitioner; 1975 Oct; 215(1288):508-19. PubMed ID: 1202471
    [No Abstract]   [Full Text] [Related]  

  • 15. [Oral estro-progestational agents and the uterine cervix].
    de Brux J
    Pathol Eur; 1972; 7(3):283-7. PubMed ID: 4657185
    [No Abstract]   [Full Text] [Related]  

  • 16. Risks and mechanisms of cardiovascular events in users of oral contraceptives.
    Meade TW
    Am J Obstet Gynecol; 1988 Jun; 158(6 Pt 2):1646-52. PubMed ID: 3287935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose oral contraceptives: progestin potency, androgenicity, and atherogenic potential.
    Ellis J
    Clin Ther; 1986; 8(6):607-18. PubMed ID: 3539347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral contraception and the risk of thromboembolism: what does it mean to clinicians and their patients?
    Drife J
    Drug Saf; 2002; 25(13):893-902. PubMed ID: 12381211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Customization of hormonal contraception].
    DE Leo V; Cianci A; DI Carlo C; Cappelli V; Fruzzetti F
    Minerva Ginecol; 2018 Feb; 70(1):1-26. PubMed ID: 29347814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of recurrent venous thromboembolism on progestin-only contraception: a cohort study.
    Le Moigne E; Tromeur C; Delluc A; Gouillou M; Alavi Z; Lacut K; Mottier D; Le Gal G
    Haematologica; 2016 Jan; 101(1):e12-4. PubMed ID: 26452982
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.